From late 2023 to early 2024, Viking Therapeutics (VKTX +0.68%) took off like a rocket, as it seemed that the clinical-stage biotech company would become the dark-horse candidate among GLP-1 stocks. Flash-forward two years, and significantly fewer investors hold a bullish view. Viking, which once traded for nearly $100 per share, now trades at just under $30. Before considering a purchase of this ...
From late 2023 to early 2024, Viking Therapeutics (VKTX +0.68%) took off like a rocket, as it seemed that the clinical-stage biotech company would become the dark-horse candidate among GLP-1 stocks. Flash-forward two years, and significantly fewer investors hold a bullish view. Viking, which once traded for nearly $100 per share, now trades at just under $30. Before considering a purchase of this once-popular and now apparently undervalued stock, keep in mind that the company faces many hurdles in taking on competitors like Novo Nordisk and Eli Lilly. Viking Therapeutics' rise and fall In the GLP-1 wars, Novo Nordisk was the early mover, obtaining approval for Wegovy from the U.S. Food and Drug Administration in June 2021. Then Eli Lilly received FDA approval to market Zepbound in November 2023. But shortly thereafter, speculative frenzy emerged about Viking Therapeutics and its VK2735 weight-loss drug candidate. Expand NASDAQ : VKTX Viking Therapeutics Today's Change ( 0.68 %) $ 0.21 Current Price $ 30.89 Key Data Points Market Cap $3.6B Day's Range $ 30.29 - $ 30.92 52wk Range $ 22.96 - $ 43.15 Volume 1.2M Avg Vol 2.3M While similar to Zepbound -- both are dual agonists that bind to both GLP-1 and GIP receptors -- VK2735 demonstrated even stronger clinical trial results at the time. Betting that another pharmaceutical company would buy Viking, investors aggressively bid up its shares early in 2024. After that, however, data from subsequent trials, including reports of worse-than-expected side effects, soured public perception. Why it's wise to stay skeptical Viking has remained a contender, but over the past two years, skepticism and uncertainty have stayed high. Its injection-based and pill-based VK2735 candidates remain at the clinical-trial stage. Meanwhile, Viking's larger competitors are making progress on new, more powerful treatments, such as Novo Nordisk's investigational dual agonist CagriSema, and Eli Lilly's triple-agonist candidate retatrutide. By the ...
Key Points Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increasing the competition with new product launches. Couple this with Viking dilution risks, and it still seems wise to stay away. 10 stocks we like better than Viking Therapeutics › From late 20...
Key Points Enthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason. While Viking is still trying to bring its first candidate to market, rivals are already increasing the competition with new product launches. Couple this with Viking dilution risks, and it still seems wise to stay away. 10 stocks we like better than Viking Therapeutics › From late 2023 to early 2024, Viking Therapeutics (NASDAQ: VKTX) took off like a rocket, as it seemed that the clinical-stage biotech company would become the dark-horse candidate among GLP-1 stocks. Flash-forward two years, and significantly fewer investors hold a bullish view. Viking, which once traded for nearly $100 per share, now trades at just under $30. Before considering a purchase of this once-popular and now apparently undervalued stock, keep in mind that the company faces many hurdles in taking on competitors like Novo Nordisk and Eli Lilly. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Viking Therapeutics' rise and fall In the GLP-1 wars, Novo Nordisk was the early mover, obtaining approval for Wegovy from the U.S. Food and Drug Administration in June 2021. Then Eli Lilly received FDA approval to market Zepbound in November 2023. But shortly thereafter, speculative frenzy emerged about Viking Therapeutics and its VK2735 weight-loss drug candidate. While similar to Zepbound -- both are dual agonists that bind to both GLP-1 and GIP receptors -- VK2735 demonstrated even stronger clinical trial results at the time. Betting that another pharmaceutical company would buy Viking, investors aggressively bid up its shares early in 2024. After that, however, data from subsequent trials, including reports of worse-than-expected side effects, soured public perception. Why it's wise to stay skeptical Viking has remai...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Santa Clara County filed a civil lawsuit against Meta Platforms (NasdaqGS:META), accusing it of knowingly profiting from scam ads that use AI systems. The suit targets Meta's advertising practices and claims the company prioritizes revenue over user safety. Al...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Santa Clara County filed a civil lawsuit against Meta Platforms (NasdaqGS:META), accusing it of knowingly profiting from scam ads that use AI systems. The suit targets Meta's advertising practices and claims the company prioritizes revenue over user safety. Alleged victims include seniors and small businesses that were defrauded through sophisticated scam campaigns. The case seeks financial penalties and broad changes to how Meta screens and serves ads on its platforms. Meta Platforms, the parent company of Facebook and Instagram, relies heavily on targeted digital advertising across its social media apps and services. As AI tools become more capable, they are increasingly used to create and distribute convincing scam content, which is drawing closer scrutiny from regulators and local authorities. For investors, the lawsuit raises questions about potential changes to Meta's ad review systems, data practices, and AI tools, along with possible financial penalties. It also adds a fresh legal and reputational risk to monitor alongside existing regulatory attention on social media platforms and online advertising models. Stay updated on the most important news stories for Meta Platforms by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Meta Platforms. NasdaqGS:META 1-Year Stock Price Chart Does the team leading Meta Platforms have what it takes? See our full breakdown of the management team's track record and compensation. This lawsuit puts Meta’s executive leadership and governance squarely in focus. County officials claim Meta tracked billions of scam ads and generated around US$7b a year in what internal documents reportedly call “violating revenue,” while still prioritizing ad income. For you, the key question is whether leadership treats this as a one off legal issu...
By the time Jalaj Jha begins getting ready for work each morning, he already feels drained. Awakening in a cramped room in Delhi, with no ventilation except a rattling fan pushing hot air around, the 24-year-old gig worker has ahead of him a 12-hour shift delivering groceries. “I barely sleep three or four hours in this heat,” Jha said, wiping dust off his motorbike, which he uses for deliveries. ...
By the time Jalaj Jha begins getting ready for work each morning, he already feels drained. Awakening in a cramped room in Delhi, with no ventilation except a rattling fan pushing hot air around, the 24-year-old gig worker has ahead of him a 12-hour shift delivering groceries. “I barely sleep three or four hours in this heat,” Jha said, wiping dust off his motorbike, which he uses for deliveries. “I wake up exhausted. It feels like my body is pulling me down.” It is only 7am, but the temperature is already 30C (86F) – the lowest temperature of the day. During the day it can soar to more than 45C (113F). This week, Delhi registered the hottest May day in the last two years, and the warmest May night in 14 years. Rising temperatures are turning cities across south and south-east Asia into places where workers can no longer recover from the heat. A new report by US-based People’s Courage International (PCI), using research in Delhi, Dhaka, Kathmandu, Jakarta and Quezon City, has found hotter nights, combined with the urban heat island effect – the trapping of heat inside dense cities – are leaving millions of informal workers exhausted before a new workday even begins. For delivery riders, construction workers and street vendors living in cramped settlements with little ventilation or unreliable electricity, sleep itself is becoming difficult. The inability to rest and cool down is worsening heat-related illnesses, reducing productivity and pushing already vulnerable workers into deeper economic stress. View image in fullscreen Experts warn cities across the region remain poorly prepared for worsening heatwaves. Pictured: men use cloth to shield from the heat at Delhi’s Red Fort in late April. Photograph: Sajjad Hussain/AFP/Getty Images The crisis is worsening in south Asia as climate change is predicted to triple the chance of pre-monsoon heatwaves, such as a 15-day one that turned deadly last month. Scientists say night-time temperatures are rising faster than daytim...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Santa Clara County filed a civil lawsuit against Meta Platforms (NasdaqGS:META), accusing it of knowingly profiting from scam ads that use AI systems. The suit targets Meta's advertising practices and claims the company prioritizes revenue over user safety. Al...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Santa Clara County filed a civil lawsuit against Meta Platforms (NasdaqGS:META), accusing it of knowingly profiting from scam ads that use AI systems. The suit targets Meta's advertising practices and claims the company prioritizes revenue over user safety. Alleged victims include seniors and small businesses that were defrauded through sophisticated scam campaigns. The case seeks financial penalties and broad changes to how Meta screens and serves ads on its platforms. Meta Platforms, the parent company of Facebook and Instagram, relies heavily on targeted digital advertising across its social media apps and services. As AI tools become more capable, they are increasingly used to create and distribute convincing scam content, which is drawing closer scrutiny from regulators and local authorities. For investors, the lawsuit raises questions about potential changes to Meta's ad review systems, data practices, and AI tools, along with possible financial penalties. It also adds a fresh legal and reputational risk to monitor alongside existing regulatory attention on social media platforms and online advertising models. Stay updated on the most important news stories for Meta Platforms by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Meta Platforms. NasdaqGS:META 1-Year Stock Price Chart Does the team leading Meta Platforms have what it takes? See our full breakdown of the management team's track record and compensation. This lawsuit puts Meta’s executive leadership and governance squarely in focus. County officials claim Meta tracked billions of scam ads and generated around US$7b a year in what internal documents reportedly call “violating revenue,” while still prioritizing ad income. For you, the key question is whether leadership treats this as a one off legal issu...
BlackRock (BLK +0.88%) has limited withdrawals from a large private credit fund. Blue Owl Capital (OWL 1.37%) has done the same thing with some of its private business development companies (BDCs). These decisions signal that Wall Street is nervous about private credit markets. And still JPMorgan Chase (JPM +1.15%) is happy to have $50 billion in exposure to the space. Should you be OK with that? ...
BlackRock (BLK +0.88%) has limited withdrawals from a large private credit fund. Blue Owl Capital (OWL 1.37%) has done the same thing with some of its private business development companies (BDCs). These decisions signal that Wall Street is nervous about private credit markets. And still JPMorgan Chase (JPM +1.15%) is happy to have $50 billion in exposure to the space. Should you be OK with that? It's all relative. All in vs. just a part of a bigger business Business development companies are, effectively, 100% focused on private credit. If Wall Street turns away from the sector, BDCs will likely suffer. The fact that sizable withdrawal requests are leading private BDCs to limit withdrawals is not a good sign. JPMorgan CEO Jamie Dimon believes that the credit cycle will eventually turn, and that losses on leverages loans will be material. Nor is he surprised that investors are trying to get ahead of the curve here, given that information about private credit loans is a bit opaque. However, Dimon doesn't run a BDC. He runs a massive, $800 billion market-cap, highly diversified financial institution. His firm's $50 billion in exposure to private credit is fairly modest compared to the company's size, even though that exposure is much larger than peers like Wells Fargo (WFC +0.63%) and Citigroup (C 0.10%), which have exposure of around $36 billion and $22 billion, respectively. There's another scale difference here: Citigroup and Wells Fargo have market caps closer to $200 billion. JPMorgan has the scale to take on more private credit risk than its smaller peers. Expand NYSE : JPM JPMorgan Chase Today's Change ( 1.15 %) $ 3.49 Current Price $ 306.49 Key Data Points Market Cap $821B Day's Range $ 303.99 - $ 307.42 52wk Range $ 260.31 - $ 337.25 Volume 249.8K Avg Vol 9.5M Dividend Yield 1.93 % But don't stop there. Dimon points out that the size of the private credit market is about $1.8 trillion. That's roughly the same size as the high-yield bond and the leveraged loan...